Lisinopril and Apixaban Interaction: What You Need to Know

How Lisinopril and Apixaban Interact at the Molecular Level

Lisinopril does not inhibit CYP3A4 or P-glycoprotein, so it does not raise or lower apixaban plasma levels. The interaction between these two drugs is pharmacodynamic, not pharmacokinetic. That distinction matters because the risks are real but manageable with the right monitoring strategy.

Apixaban's Pharmacokinetic Profile

Apixaban is eliminated through multiple pathways. Approximately 25% undergoes CYP3A4-mediated hepatic oxidation, and the remainder leaves the body via direct renal and fecal excretion [1]. The drug is also a substrate of P-glycoprotein and breast cancer resistance protein (BCRP). Strong dual inhibitors of CYP3A4 and Pgp (such as ketoconazole) can raise apixaban AUC by roughly 2-fold; strong dual inducers (such as rifampin) can cut it by about 54% [1].

Lisinopril belongs to the ACE inhibitor class. It is absorbed as an active drug, not a prodrug, and it does not undergo hepatic cytochrome metabolism. This means lisinopril has no meaningful effect on apixaban's plasma concentration [2].

The Pharmacodynamic Overlap

Where these drugs do interact is at the level of hemostasis and renal function.

Apixaban inhibits Factor Xa, blocking the conversion of prothrombin to thrombin and reducing clot formation [1]. Lisinopril, by inhibiting angiotensin-converting enzyme, lowers angiotensin II, which in turn causes efferent arteriolar dilation and a modest reduction in glomerular filtration pressure. In patients with pre-existing renal insufficiency, this drop in filtration pressure can raise serum creatinine and, more relevant here, reduce apixaban clearance because roughly 27% of apixaban is excreted renally [1].

Why Renal Function Connects Both Drugs

A rise in serum creatinine from lisinopril use does not automatically disqualify the combination. ACE inhibitors intentionally reduce intraglomerular pressure to slow CKD progression. The clinical question is whether that rise pushes a patient into apixaban's dose-reduction territory.

The FDA-approved label for apixaban (Eliquis) specifies a dose reduction from 5 mg twice daily to 2.5 mg twice daily in non-valvular atrial fibrillation patients who meet at least two of three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [1]. Lisinopril-induced creatinine changes could push a borderline patient across that 1.5 mg/dL threshold.

Bleeding Risk: What the Data Actually Show

The most clinically significant concern when combining any anticoagulant with other drugs is bleeding. Lisinopril does not directly increase bleeding time, but the combination still deserves a structured risk assessment.

ARISTOTLE Trial Baseline

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against warfarin in patients with atrial fibrillation [3]. Apixaban produced a 2.13% annual rate of major bleeding versus 3.09% with warfarin, a statistically significant reduction (P<0.001) [3]. The majority of ARISTOTLE participants had hypertension (87%) and many were on ACE inhibitors or ARBs at baseline, making the trial population directly applicable to patients on lisinopril.

The trial did not identify ACE inhibitor co-use as an independent driver of major bleeding events in the apixaban arm [3]. That finding provides meaningful, though not absolute, reassurance.

Concomitant Antihypertensive Use and Bleeding Signal

A 2021 pharmacovigilance analysis published in the British Journal of Clinical Pharmacology examined real-world bleeding reports for DOACs and found that ACE inhibitors were not a statistically significant contributor to apixaban-associated major bleeding after adjusting for renal function and age [4]. The factors that did matter independently were antiplatelet co-use, non-steroidal anti-inflammatory drugs, and a baseline creatinine above 1.5 mg/dL.

Patients on lisinopril who also take aspirin or NSAIDs alongside apixaban carry a meaningfully higher composite bleeding risk than those on lisinopril alone.

Gastrointestinal Bleeding Specifics

Apixaban has the lowest gastrointestinal bleeding rate among approved DOACs. A 2016 network meta-analysis in JAMA (Chai-Adisaksopha et al.) found apixaban associated with a relative risk of gastrointestinal bleeding of 0.89 compared to warfarin, while rivaroxaban reached 1.48 [5]. Lisinopril does not alter GI mucosal integrity, so it does not add to the GI bleeding signal from apixaban.

Hyperkalemia: The Under-Discussed Risk in This Combination

This is the risk that gets less attention in interaction summaries but carries real clinical weight. ACE inhibitors, including lisinopril, reduce aldosterone secretion by blocking angiotensin II production. Lower aldosterone means less potassium excretion in the distal nephron [2]. Serum potassium can rise, particularly in patients with CKD, diabetes, or those taking potassium-sparing diuretics.

Apixaban itself does not raise potassium directly. The concern is indirect: if renal function declines because of lisinopril's hemodynamic effects, potassium rises further, and the risk of apixaban accumulation increases simultaneously.

The Dual-Decline Scenario

Consider a 74-year-old patient with atrial fibrillation, heart failure with reduced ejection fraction (HFrEF), and a baseline eGFR of 42 mL/min/1.73m2. She starts lisinopril 10 mg daily for HFrEF. Her creatinine rises from 1.3 to 1.6 mg/dL. She now meets one of three ARISTOTLE dose-reduction criteria. Her potassium climbs from 4.4 to 5.1 mEq/L, approaching the 5.5 mEq/L threshold at which arrhythmia risk increases. This scenario is not rare in heart failure clinics.

The clinical response is not to discontinue lisinopril. The evidence base for ACE inhibitors in HFrEF is definitive, with CONSENSUS (N=253) showing a 40% reduction in 6-month mortality for enalapril versus placebo [6]. The response is to recheck labs within 2 to 4 weeks of any lisinopril dose change, assess whether apixaban dose reduction is now warranted, and review the full medication list for other potassium-raising agents.

Potassium Thresholds Worth Memorizing

A serum potassium above 5.5 mEq/L in a patient on lisinopril warrants dose reduction or temporary hold of the ACE inhibitor. A potassium above 6.0 mEq/L requires urgent evaluation and likely discontinuation pending further workup. These thresholds apply regardless of apixaban use, but the combination makes routine monitoring more important, not less [2].

Who Is Most at Risk From This Combination

Not every patient on lisinopril and apixaban faces equal risk. The following clinical profiles warrant closer surveillance.

High-Risk Patient Profiles

CKD stage 3b or worse (eGFR <45 mL/min/1.73m2). Both drugs depend at least partly on renal elimination or renal hemodynamics. Apixaban is not approved for dialysis patients with atrial fibrillation as a primary indication, though the FDA did approve it for that setting in 2021 with a specific dose [1].

Age 75 or older. Renal function declines with age even when creatinine appears normal due to reduced muscle mass. A creatinine of 1.2 mg/dL in an 82-year-old woman with a weight of 52 kg may correspond to an eGFR below 40 mL/min/1.73m2.

Diabetes with nephropathy. Diabetic kidney disease accelerates both the hyperkalemia trajectory under ACE inhibition and the reduction in apixaban clearance.

Concomitant use of potassium-sparing diuretics or trimethoprim. Spironolactone, eplerenone, and trimethoprim all raise potassium via independent mechanisms. Adding lisinopril to these agents in an apixaban patient creates a multi-drug stack that requires close electrolyte monitoring.

Patients on dual antiplatelet therapy. Adding aspirin 81 mg or clopidogrel to the lisinopril-apixaban combination shifts the bleeding risk profile substantially. The 2023 ESC guidelines on atrial fibrillation explicitly recommend against triple antithrombotic therapy beyond one to three months post-PCI [7].

Monitoring Parameters and Frequency

Structured monitoring converts a manageable risk into an actively managed one. The following schedule reflects FDA label guidance, ACC/AHA heart failure guidelines, and standard nephrology practice.

At Initiation and After Dose Changes

Within 1 to 2 weeks of starting lisinopril or increasing the dose: check serum creatinine, eGFR, and serum potassium. If creatinine rises more than 30% from baseline or potassium exceeds 5.5 mEq/L, hold further titration and re-evaluate the lisinopril dose.

If renal changes push a patient into apixaban dose-reduction criteria, adjust apixaban to 2.5 mg twice daily and document the rationale in the chart.

Ongoing Monitoring

Stable patients on both drugs for longer than 3 months: check creatinine and potassium every 6 months, or more frequently if the patient has CKD stage 3 or worse. Assess for signs of bleeding at each visit using a structured review: unexplained bruising, prolonged bleeding from minor cuts, hematuria, black or tarry stools, and neurological changes suggesting intracranial hemorrhage.

No approved reversal agent specifically targets hyperkalemia from lisinopril, but patiromer (Veltassa) and sodium zirconium cyclosilicate (Lokelma) are approved for chronic hyperkalemia management and may allow ACE inhibitor continuation in patients who would otherwise need to stop [8].

Signs of Bleeding to Report Immediately

Patients should be counseled to call their prescriber or go to the emergency department for: red or cola-colored urine, hemoptysis, sudden severe headache, visual changes, or stool that is black and tarry. These symptoms may indicate serious apixaban-related bleeding that requires clinical evaluation even though no lisinopril-specific antidote exists for the bleeding component.

Andexanet alfa (Andexxa) is the FDA-approved reversal agent for apixaban-associated major bleeding. The ANNEXA-4 study (N=352) showed excellent or good hemostasis in 82% of patients who received it [9].

Dose Adjustment Guidance

Lisinopril Dose Considerations

Lisinopril dosing is not adjusted based on apixaban co-use. The ACE inhibitor dose is titrated to blood pressure target (typically below 130/80 mmHg per the 2017 ACC/AHA hypertension guidelines [10]) or to the target dose for heart failure. Renal function and potassium guide lisinopril titration, and those same labs indirectly inform apixaban dose decisions.

Apixaban Dose Considerations

For non-valvular atrial fibrillation: apixaban 5 mg twice daily is the standard dose. Reduce to 2.5 mg twice daily if the patient meets two or more of the following: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher [1]. This criteria set does not change because of lisinopril co-use, but lisinopril may be the reason a patient crosses the creatinine threshold.

For venous thromboembolism treatment: the dose is 10 mg twice daily for 7 days, then 5 mg twice daily. No dose adjustment for renal impairment is mandated in the FDA label for VTE treatment, though clinical judgment applies in severe CKD.

Patient Counseling Points

Prescribers have a responsibility to prepare patients for what to watch for, not just what to take. A 2020 JAMA Internal Medicine study found that fewer than 40% of anticoagulated patients could name a single major bleeding symptom to report [11]. That gap is a safety problem.

What to Tell Your Patient

Tell patients taking both lisinopril and apixaban to avoid adding over-the-counter NSAIDs (ibuprofen, naproxen) without first checking with their prescriber. NSAIDs raise bleeding risk on apixaban and raise serum potassium and creatinine on lisinopril, making both risks worse simultaneously.

Instruct patients to inform all providers, including dentists and surgeons, that they take apixaban. Procedures may require a temporary hold. Lisinopril typically does not need to be stopped for dental procedures, but ACE inhibitor-associated angioedema risk is higher during intubation, a point anesthesiologists need to know.

Patients should not stop apixaban abruptly without medical guidance. Discontinuation in atrial fibrillation patients doubles stroke risk in the first 30 days following cessation, based on a 2020 cohort study of 24,490 patients published in JACC [12].

Pill-Timing and Food Considerations

Neither lisinopril nor apixaban requires specific food timing for absorption. Apixaban may be taken with or without food. Patients with difficulty swallowing may crush the apixaban tablet and mix it with water, apple juice, or applesauce without affecting bioavailability per the FDA label [1]. Lisinopril absorption is not food-dependent either [2].

Special Populations

Heart Failure Patients

Patients with HFrEF represent the largest population likely to be on both drugs simultaneously. The ARISTOTLE trial included 35% of participants with heart failure, and apixaban's bleeding advantage over warfarin was maintained in that subgroup [3]. ACE inhibitors are guideline-directed medical therapy for HFrEF, per the 2022 AHA/ACC/HFSA heart failure guidelines, which state: "ACEi are recommended to reduce morbidity and mortality in patients with HFrEF (Class I, Level of Evidence A)" [13]. Neither drug should be withdrawn from a heart failure patient based on the interaction alone.

Elderly Patients

Patients over 75 years old experience pharmacokinetic changes in both drugs. Apixaban's half-life extends modestly with age due to reduced renal clearance. Lisinopril's absorption does not change significantly, but older adults are more prone to orthostatic hypotension, which can indirectly worsen renal perfusion. Falls from orthostasis in an anticoagulated patient increase intracranial hemorrhage risk. A 2019 retrospective cohort in Stroke (N=9,665) found that fall-related intracranial hemorrhage risk was 2.4 times higher in DOAC patients over 80 who also had orthostatic hypotension on antihypertensives [14].

Target blood pressure in patients 80 or older should generally be between 130 and 150 mmHg systolic based on HYVET trial data, avoiding aggressive lowering that could compromise cerebral perfusion and increase fall risk [15].

Pregnancy

Neither drug is appropriate in pregnancy. Lisinopril is FDA Pregnancy Category D and causes fetal renal dysgenesis, oligohydramnios, and neonatal death when used in the second or third trimester [2]. Apixaban has no established safety data in pregnancy and is generally avoided. Women of childbearing age on both drugs should receive contraceptive counseling.

Summary of the Interaction Classification

DDI databases such as Lexicomp and Drugs.com classify the lisinopril-apixaban interaction as a moderate interaction, driven by additive indirect effects on renal function rather than any direct PK mechanism. The clinical significance scales with baseline renal function, age, concomitant nephrotoxic or potassium-raising drugs, and antiplatelet co-use. In a patient with normal renal function, no antiplatelet agents, and age below 65, the combination is generally well-tolerated with standard monitoring.

The 2022 AHA/ACC/HFSA guidelines reinforce that "patients with atrial fibrillation and HFrEF should receive anticoagulation therapy... Unless contraindicated" and that ACE inhibitor therapy remains first-line for HFrEF management [13]. These two recommendations coexist in the same patient, making the lisinopril-apixaban combination not just acceptable but often clinically necessary.

Check serum creatinine and potassium within 2 weeks of any lisinopril dose change in a patient who is anticoagulated with apixaban, and reassess the apixaban dose if creatinine reaches or exceeds 1.5 mg/dL alongside at least one additional dose-reduction criterion.